News Release
For Immediate Release
June 14, 2018
Sawai Pharmaceutical Co., Ltd.

Sawai Pharmaceutical Launches 7 Compounds with 17 Strengths of Generic Drugs
Osaka, Japan –June 14, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan,President: Mitsuo Sawai) today announced the launch of 7 compounds with 17 strengths of genericdrugs. Sawai’s product line now includes 302 compounds with 738 strengths.
The list of new products:
1. ILUAMIX® Combination Tablets LD [SAWAI] / HD [SAWAI]
・Generic name:・Indications:・Brand products:

Irbesartan / Amlodipine Besilate
Hypertension
AIMIX® Combination Tablets LD / HD

2. Bepotastine Besilate OD Tablets 5 mg [SAWAI] / 10 mg [SAWAI],
Bepotastine Besilate Tablets 5 mg [SAWAI] / 10 mg [SAWAI]
・Generic name:・Indications:・Brand products:

Bepotastine Besilate
Allergic rhinitis, urticaria, and pruritus associated with dermatitis (eczema/skininflammation, prurigo, pruritus cutaneous)
TALION® OD Tablets 5 mg / 10mg, TALION® Tablets 5 mg / 10 mg

3. Minodronic Acid Tablets 1 mg [SAWAI] / 50 mg [SAWAI]
・Generic name:Minodronic Acid Hydrate・Indications:
Osteoporosis
・Brand products:
Bonoteo® Tablets 1 mg / 50 mg, RECALBON® Tablets 1 mg / 50mg
・Striking features: To promote proper use of the product and for patients’convenience, the instruction card is applied directly to the blister
pack. This special feature is being used for the first time in theJapanese generics industry. This package is a patient friendly
design. Folding the instruction card in half allows the patient toremove the tablet easily from the blister pack. Dosage andadministration instructions are prominently displayed as thisdrug is directed to be taken as 1 tablet at a time once every 4weeks.
4. Lamotrigine Tablets 25 mg [SAWAI] / 100 mg [SAWAI],
Lamotrigine Tablets for Pediatric 2 mg [SAWAI] / 5 mg [SAWAI]
・Generic name:・Indications:・Brand products:

Lamotrigine
Monotherapy for the following seizures in patients with epilepsy
・partial-onset seizures
・tonic-clonic seizures
Adjunctive therapy for the following seizures in patients not having obtained
sufficient efficacy with other antiepileptic drugs
・partial seizures
・tonic-clonic seizures
・generalized seizures associated with Lennox-Gastaut syndrome
Suppression of recurrent/relapsed mood episode in patients with bipolar
disorderLamictal ® Tablets 25 mg / 100 mg, Lamictal ® Tablets for Pediatric 2 mg / 5mg

News Release
5. Nalfurafine Hydrochloride OD Tablets 2.5 μg [SAWAI]
・Generic name:・Indications:Nalfurafine Hydrochloride
Improvement of pruritus in the hemodialysis patients (use only when sufficientefficacy is not obtained with the existing therapies or treatments)
・Brand products:
REMITCH® OD Tablets 2.5 μg / Capsules 2.5 μg
NOPICOR® Capsules 2.5 μg
・Striking features: Since water intake is sometimes restricted for dialysis patients Sawai
aimed to reduce the dose burden of patients by developing OD tablets
which can be taken without water.

6. Lanthanum Carbonate Granules Sachet 250 mg [SAWAI] / 500 mg [SAWAI]
・Generic name:・Indications:・Brand products:

Lanthanum carbonate hydrate
Improvement of hyperphosphatemia in patients with chronic kidney disease
Fosrenol® Granules Sachet 250 mg / 500 mg

7. Oseltamivir Capsules 75 mg [SAWAI] / DS 3% [SAWAI]
・Generic name:
Oseltamivir phosphate・Indications:
Treatment or prophylaxis of influenza type A or B virus infection
・Brand products:TAMIFLU ® Capsules 75 / Dry Syrup 3%
・Striking features: TAMIFLU plays an important role in preparation for an influenza

pandemic. Only Sawai is able to launch this product.
A special feature of packages:

Product name is visible even when the lid of thebox is opened.
This feature supports medical experts to easily
confirm the product name when returning theblister packs to the box.

◆ Contact Information ◆PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.
E-mail：koho@sawai.co.jp